Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients
During the COVID-19 pandemic, approximately 15% of patients with severe COVID-19 pneumonia were reported to have neutralizing anti-type I interferon (IFN) autoantibodies, which impaired the antiviral response and led to a poorer prognosis. However, the…